Elekta AB, commonly known as Elekta, is a leading innovator in the field of medical technology, headquartered in Stockholm, Sweden (SE). Founded in 1972, the company has established itself as a key player in the oncology and neurosurgery sectors, providing advanced solutions for cancer treatment and brain disorders. Elekta's core offerings include state-of-the-art radiation therapy systems, software solutions for treatment planning, and comprehensive patient management tools. What sets Elekta apart is its commitment to precision and personalised care, utilising cutting-edge technology to enhance treatment outcomes. With a strong presence in Europe, North America, and Asia, Elekta has achieved significant milestones, including numerous awards for innovation and excellence in healthcare. The company continues to lead the market, driven by its mission to improve the lives of patients worldwide through advanced medical solutions.
How does Elekta's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Elekta's score of 77 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Elekta reported total carbon emissions of approximately 541,542,000 kg CO2e, with Scope 1 emissions at about 6,141,000 kg CO2e, Scope 2 emissions at approximately 3,760,000 kg CO2e (market-based), and a significant Scope 3 total of around 531,640,000 kg CO2e. This represents a slight increase from 2023, where total emissions were about 508,029,000 kg CO2e, with Scope 1 at 4,442,000 kg CO2e, Scope 2 at 3,347,000 kg CO2e, and Scope 3 at approximately 500,240,000 kg CO2e. Elekta has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 46.2% by FY2031 from a FY2021 baseline. Additionally, the company plans to increase its annual sourcing of renewable electricity from 61% in FY2021 to 100% by FY2030. For Scope 3 emissions, Elekta targets a 55% reduction per radiotherapy cancer treatment course by FY2031, also from a FY2021 base year. Furthermore, the company commits that 45% of its suppliers, based on emissions, will have science-based targets by FY2026. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect Elekta's commitment to addressing climate change within the healthcare equipment and supplies sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | - | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,576,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 444,082,520 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Elekta's Scope 3 emissions, which decreased by 13% last year and increased by approximately 20% since 2020, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Use of Sold Products" being the largest emissions source at 49% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Elekta has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Elekta's sustainability data and climate commitments